{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEET\t(Unaudited)\tApril 2,\tDecember 31,\t(In millions except share and per share amounts)\t2022\t2021\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t2,752\t$\t4,477\tAccounts receivable, less allowances of $\t170\tand $\t150\t7,889\t7,977\tInventories\t5,483\t5,051\tContract assets, net\t1,064\t968\tOther current assets\t1,588\t1,640\tTotal current assets\t18,776\t20,113\tProperty, plant and equipment, net\t8,448\t8,333\tAcquisition-related intangible assets, net\t19,378\t20,113\tOther assets\t4,424\t4,640\tGoodwill\t41,721\t41,924\tTotal assets\t$\t92,747\t$\t95,123\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t1,866\t$\t2,537\tAccounts payable\t2,667\t2,867\tAccrued payroll and employee benefits\t1,634\t2,427\tContract liabilities\t2,871\t2,655\tOther accrued expenses\t3,032\t2,950\tTotal current liabilities\t12,070\t13,436\tDeferred income taxes\t3,493\t3,837\tOther long-term liabilities\t4,664\t4,540\tLong-term obligations\t31,389\t32,333\tRedeemable noncontrolling interest\t113\t122\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t439,530,820\tand\t439,154,741\tshares issued\t440\t439\tCapital in excess of par value\t16,292\t16,174\tRetained earnings\t37,528\t35,431\tTreasury stock at cost,\t48,068,820\tand\t44,720,112\tshares\t(\t10,961\t)\t(\t8,922\t)\tAccumulated other comprehensive items\t(\t2,343\t)\t(\t2,329\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t40,956\t40,793\tNoncontrolling interests\t62\t62\tTotal equity\t41,018\t40,855\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t92,747\t$\t95,123\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3\tTHERMO FISHER SCIENTIFIC INC.\tCONDENSED CONSOLIDATED STATEMENT OF INCOME\t(Unaudited)\tThree months ended\tApril 2,\tApril 3,\t(In millions except per share amounts)\t2022\t2021\tRevenues\tProduct revenues\t$\t8,017\t$\t7,856\tService revenues\t3,801\t2,050\tTotal revenues\t11,818\t9,906\tCosts and operating expenses:\tCost of product revenues\t3,555\t3,327\tCost of service revenues\t2,799\t1,370\tSelling, general and administrative expenses\t2,277\t1,826\tResearch and development expenses\t364\t320\tRestructuring and other costs\t2\t14\tTotal costs and operating expenses\t8,997\t6,857\tOperating income\t2,821\t3,049\tInterest income\t18\t12\tInterest expense\t(\t136\t)\t(\t125\t)\tOther income/(expense)\t(\t163\t)\t(\t183\t)\tIncome before income taxes\t2,540\t2,753\tProvision for income taxes\t(\t301\t)\t(\t416\t)\tEquity in earnings/(losses) of unconsolidated entities\t(\t19\t)\t \tNet income\t2,220\t2,337\tLess: net income attributable to noncontrolling interests and redeemable noncontrolling interest\t5\t \tNet income attributable to Thermo Fisher Scientific Inc.\t$\t2,215\t$\t2,337\tEarnings per share attributable to Thermo Fisher Scientific Inc.\tBasic\t$\t5.66\t$\t5.93\tDiluted\t$\t5.61\t$\t5.88\tWeighted average shares\tBasic\t392\t394"
        ],
        "timestamp": "2025-01-21_09-41-35"
    }
}